Risk-Guided Strategy to Prevent Cytomegalovirus Associated Complications After Liver Transplantation

References

• Arvin A , Campadelli-FiumeG, MocarskiEet al. Human herpesviruses . In : Biology, Therapy, and Immunoprophylaxis . Cambridge University Press, Cambridge, UK ( 2007 ).
   Google Scholar
• Manicklal S , EmeryVC, LazzarottoT, BoppanaSB, GuptaRK . The ‘silent’ global burden of congenital cytomegalovirus . Clin. Microbiol. Rev.26 ( 1 ), 86 – 102 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Asberg A , JardineAG, BignaminiAAet al. Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients . Am. J. Transpl.10 ( 8 ), 1881 – 1888 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Stern M , HirschH, CusiniAet al. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment . Transplantation98 ( 9 ), 1013 – 1018 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Emery VC , AsherK, Sanjuan C deJ . Importance of the cytomegalovirus seropositive recipient as a contributor to disease burden after solid organ transplantation . J. Clin. Virol.54 ( 2 ), 125 – 129 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kotton CN , KumarD, CaliendoAMet al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation . Transplantation doi:10.1097/TP.0000000000002191 ( 2018 ) ( Epub ahead of print ).
   Google Scholar
• Asberg A , HumarA, JardineAGet al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients . Am. J. Transpl.9 ( 5 ), 1205 – 1213 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Asberg A , HumarA, RollagHet al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients . Am. J. Transpl.7 ( 9 ), 2106 – 2113 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Humar A , PayaC, PescovitzMDet al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients . Am. J. Transpl.4 ( 4 ), 644 – 649 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Kim JM , KwonCHD, JohJ-Wet al. Oral valganciclovir as a preemptive treatment for cytomegalovirus (CMV) infection in CMV-seropositive liver transplant recipients . PLoS ONE10 ( 5 ), e0123554 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Lautenschlager I , LoginovR, MäkisaloH, HöckerstedtK . Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis . J. Clin. Virol.71, 73 – 75 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Le Page AK , JagerMM, KottonCN, Simoons-SmitA, RawlinsonWD . International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines . Transplantation95 ( 12 ), 1455 – 1460 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Len O , GavaldàJ, AguadoJMet al. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients . Clin. Infect. Dis.46 ( 1 ), 20 – 27 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Paya C , HumarA, DominguezEet al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients . Am. J. Transpl.4 ( 4 ), 611 – 620 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Pescovitz MD , RabkinJ, MerionRMet al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients . Antimicrob. Agents Chemother.44 ( 10 ), 2811 – 2815 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Rayes N , SeehoferD, SchmidtCAet al. Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation . Transplantation72 ( 5 ), 881 – 885 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Simon P , SasseM, LaudiSet al. Two strategies for prevention of cytomegalovirus infections after liver transplantation . World J. Gastroenterol.22 ( 12 ), 3412 – 3417 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Singh N , WannstedtC, KeyesLet al. Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts . Liver Transpl.14 ( 2 ), 240 – 244 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Togashi J , SugawaraY, HashimotoMet al. Oral valganciclovir versus intravenous ganciclovir as preemptive treatment for cytomegalovirus infection after living donor liver transplantation: a randomized trial . Biosci. Trends5 ( 5 ), 217 – 222 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Mengelle C , RostaingL, WeclawiakH, RossignolC, KamarN, IzopetJ . Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients . J. Med. Virol.87 ( 5 ), 836 – 844 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Mumtaz K , FaisalN, HusainS, MorilloA, RennerEL, ShahPS . Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis . Am. J. Transpl.15 ( 2 ), 472 – 481 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Onor IO , ToddSB, MeredithEet al. Evaluation of clinical outcomes of prophylactic versus pre-emptive cytomegalovirus strategy in liver transplant recipients . Transpl. Int.26 ( 6 ), 592 – 600 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Shi X-L , de Mare-BredemeijerELD, TapirdamazÖet al. CMV primary infection is associated with donor-specific T cell hyporesponsiveness and fewer late acute rejections after liver transplantation . Am. J. Transpl.15 ( 9 ), 2431 – 2442 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Litjens NHR , van der WagenL, KuballJ, KwekkeboomJ . Potential beneficial effects of cytomegalovirus infection after transplantation . Front. Immunol.9, 389 ( 2018 ).
   PubMed Web of Science ®Google Scholar
• Jain A , OrloffM, KashyapRet al. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients? Transplant. Proc. 37 ( 7 ), 3182 – 3186 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Simon P , SasseM, LaudiSet al. Two strategies for prevention of cytomegalovirus infections after liver transplantation . World J. Gastroenterol.22 ( 12 ), 3412 – 3417 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Perrella A , EspositoC, IoiaG, CampanellaL, TaglialatelaD, CuomoO . Cytomegalovirus infection after liver transplantation: prophylaxis and preemptive treatment–a single-center experience . Transplant. Proc.42 ( 4 ), 1226 – 1228 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Díaz-Pedroche C , LumbrerasC, Del VallePet al. Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients . Transpl. Proc.37 ( 9 ), 3766 – 3767 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Manuel O , KralidisG, MuellerNJet al. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients . Am. J. Transpl.13 ( 9 ), 2402 – 2410 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Opelz G , DöhlerB, RuhenstrothA . Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report . Am. J. Transpl.4 ( 6 ), 928 – 936 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Kliem V , FrickeL, WollbrinkT, BurgM, RadermacherJ, RohdeF . Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial . Am. J. Transpl.8 ( 5 ), 975 – 983 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Atabani SF , SmithC, AtkinsonCet al. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by pre-emptive therapy . Am. J. Transpl.12 ( 9 ), 2457 – 2464 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Witzke O , HauserIA, BartelsM, WolfG, WoltersH, NitschkeM . Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial . Transplantation93 ( 1 ), 61 – 68 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Humar A , LimayeAP, BlumbergEAet al. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study . Transplantation90 ( 12 ), 1427 – 1431 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Khoury JA , StorchGA, BohlDLet al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients . Am. J. Transpl.6 ( 9 ), 2134 – 2143 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Ahlenstiel-Grunow T , KochA, GroßhennigAet al. A multicenter, randomized, open-labeled study to steer immunosuppressive and antiviral therapy by measurement of virus (CMV, ADV, HSV)-specific T cells in addition to determination of trough levels of immunosuppressants in pediatric kidney allograft recip . Trials15 ( 1 ), 324 ( 2014 ).
   PubMedGoogle Scholar
• McIntosh M , HauschildB, MillerV . Human cytomegalovirus and transplantation: drug development and regulatory issues . J. Virus Erad.2 ( 3 ), 143 – 148 ( 2016 ).
   PubMed Web of Science ®Google Scholar